Abstract
Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinsons disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinsons disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinsons disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Keywords: Free radicals, oxidative stress, Parkinson's disease, Alzheimer's disease, beta amyloid, neurodegeneration, fibrils, neurotrophic factors, neurogenesis
Current Topics in Medicinal Chemistry
Title: Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease
Volume: 8 Issue: 12
Author(s): Giulia Ferrari-Toninelli, Sara A. Bonini, Giovanna Cenini, Giuseppina Maccarinelli, Mariagrazia Grilli, Daniela Uberti and Maurizio Memo
Affiliation:
Keywords: Free radicals, oxidative stress, Parkinson's disease, Alzheimer's disease, beta amyloid, neurodegeneration, fibrils, neurotrophic factors, neurogenesis
Abstract: Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinsons disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinsons disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinsons disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Export Options
About this article
Cite this article as:
Ferrari-Toninelli Giulia, Bonini A. Sara, Cenini Giovanna, Maccarinelli Giuseppina, Grilli Mariagrazia, Uberti Daniela and Memo Maurizio, Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease, Current Topics in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/156802608785161402
DOI https://dx.doi.org/10.2174/156802608785161402 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complexity in Protein Folding: Simulation Meets Experiment
Current Physical Chemistry Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Current Medicinal Chemistry Efforts to Understand the Molecular Basis of Hypertension Through Drug:Membrane Interactions
Current Topics in Medicinal Chemistry Microwave-Assisted Multicomponent Reactions in the Heterocyclic Chemistry
Current Organic Chemistry Recent Progress in the Development of Small Molecule c-Met Inhibitors
Current Topics in Medicinal Chemistry Brain Molecules and Appetite: The Case of Oleoylethanolamide
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Difference Between Accuracy- and Error-Related Brain Activity with Varying Memory Load in Maintenance Phase of Working Memory
Neuroscience and Biomedical Engineering (Discontinued) EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews Entrainment of the Human Circadian Clock to the Light-Dark Cycle and its Impact on Patients in the ICU and Nursing Home Settings
Current Pharmaceutical Design Histone Deacetylation and Motor Neuron Degeneration
CNS & Neurological Disorders - Drug Targets The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
Current Neuropharmacology Intracranial Venous Haemodynamics in Multiple Sclerosis
Current Neurovascular Research GEPT Extract Reduces Aβ Deposition by Regulating the Balance Between Production and Degradation of Aβ in APPV717I Transgenic Mice
Current Alzheimer Research Role of PI3K/AKT/mTOR Pathway Associated Oxidative Stress and Cardiac Dysfunction in Takotsubo Syndrome
Current Neurovascular Research Prevention of Lymphocyte Neurotoxic Effects by microRNA Delivery
MicroRNA Proteomics Analysis of CA1 Region of the Hippocampus in Pre-, Progression and Pathological Stages in a Mouse Model of the Alzheimer’s Disease
Current Alzheimer Research FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Green and Highly Efficient One-Pot Synthesis of Some New Bis Thiazolidinones
Letters in Organic Chemistry Electronic and Structural Aspects of P450-Mediated Drug Metabolism
Drug Metabolism Letters